AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01597986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (ethinyl estradiol / norethindrone)
Description: contraceptive pill consisting of ethinyl estradiol and norethindrone
Study NCT01802385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
Study NCT03810183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
Study NCT03810183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
Study NCT03307174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT03307174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT03307174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT03307174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT00971113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sc-FOS and Sideritis euboea extract
Description: dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea
Study NCT00971113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sc-FOS and Sideritis euboea extract
Description: dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea
Study NCT05836480 — intervention group
Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
Study NCT00863707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: IV
Study NCT00863707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT05002972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study NCT03095807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1706 A
Description: Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
Study NCT03095807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (s.c., under the skin)
Study NCT03113045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated time
Description: Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
Study NCT03639168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with cisplatin
Description: Chidamide combined with cisplatin
Study NCT01867008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI422 Cochlear Implant with N6 Sound Processor
Study NCT00049816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: 30 minutes/day, 3 times/week for 52 weeks
Study NCT00049816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: 30 minutes/day, 3 times/week for 52 weeks
Study NCT00512590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Guided Imagery
Description: The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10.
Study NCT01578772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: 80mg tablets po daily for 6 weeks
Study NCT01837745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTSH stimulation
Description: Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
Study NCT01837745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I131
Description: An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
Study NCT01837745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: * 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
Study NCT01837745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: * 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
Study NCT03008044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense system
Description: A novel CGM system based on a FiberSense system placed through the dermis of the patient.
Study NCT02574585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal cells transplantation
Description: Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
Study NCT04072029 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification with intraocular lens implantation
Description: Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
Study NCT00745303 — intervention group
Intervention type: PROCEDURE
Intervention: Tai Chi Cuan
Description: Tai Chi Cuan training for 3 months
Study NCT03416439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: lifestyle intervention program carried out by trained professionals
Study NCT03040232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical assessment
Description: biomechanical and strength assessment of both groups
Study NCT03040232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biomechanical assessment
Description: biomechanical and strength assessment of both groups
Study NCT04056208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pistachio
Description: Unsalted pistachios
Study NCT04056208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Advice and resources will be provided
Study NCT04054830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Ophtha 1 mg/ml, GSK
Description: Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study NCT01125631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 8 weeks (4 doses total)
Study NCT00167167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer.
Study NCT04375280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness.
Description: Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)
Study NCT00469105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy/Numeracy oriented educational intervention
Description: Receives comprehensive literacy/num sensitive diabetes care
Study NCT00469105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives standard diabetes disease management
Study NCT03103984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
Study NCT04315350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Liposome
Description: Curcumin is given together with prednisolone
Study NCT04315350 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Prednisolone is given together with curcumin-placebo
Study NCT04315350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Prednisolone-placebo is given together with curcumin-placebo
Study NCT04054830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monopex 1 mg/ml, Théa
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study NCT04054830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monopex 1 mg/ml, Théa
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study NCT01741415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIDI
Study NCT01741415 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SC
Study NCT02118285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion
Study NCT02118285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
Study NCT02118285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
Study NCT02118285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
Study NCT02118285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
Study NCT02687802 — intervention group
Intervention type: OTHER
Intervention: mechanical ventilation
Description: we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
Study NCT00153426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: West Virginia WISEWOMAN
Description: Print-based tailored health communications and computer-based interactive nutrition program
Study NCT04127617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment
Study NCT04127617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nursing Educational Care
Description: Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs.
Study NCT04127617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Educational Care
Description: Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs.
Study NCT01830517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine, Losartan
Study NCT01830517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Study NCT03720886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH（1-34） 28.2μg
Description: Administered by subcutaneous injection
Study NCT03720886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH（1-34） 56.5μg
Description: Administered by subcutaneous injection
Study NCT03720886 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide acetate(Teribone™)
Description: Administered by subcutaneous injection
Study NCT03347643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS with real stimulation
Description: tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
Study NCT03347643 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS with sham stimulation
Description: Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
Study NCT03257748 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
Study NCT03257748 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LED therapy
Description: The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
Study NCT01542008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement (CAE)
Description: CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
Study NCT01542008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: broadly-directed, non-individualized education (EDU)
Description: EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed.
Study NCT00863382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Event Monitor
Description: Standard Event Monitor
Study NCT00863382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleuth Monitor
Description: Implantable Sleuth Recorder
Study NCT02125890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
Study NCT04217291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004
Description: Take orally once a day
Study NCT04217291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SY-004 matching placebo
Description: Take orally once a day
Study NCT04039724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605 + HGP0816
Study NCT04039724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1305
Study NCT03754920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged fasting
Description: Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice.
Study NCT04501250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04501250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04501250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study NCT04501250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin NPH
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study NCT00480844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
Study NCT00480844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
Study NCT04254510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial relaxation technique
Description: * Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week.
Study NCT02037893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyrine and Benzocaine otic solution
Description: antipyrine 54 mg and benzocaine 14 mg
Study NCT02037893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipyrine Otic Solution
Description: Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
Study NCT02037893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine Otic Solution
Description: benzocaine 14 mg and glycerine dehydrated to 1.0 mL
Study NCT02037893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated
Study NCT02037893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Otic solution
Description: Placebo otic solution will be glycerin that is dehydrated